Literature DB >> 17728265

The orexins/hypocretins and schizophrenia.

Ariel Y Deutch1, Michael Bubser.   

Abstract

Advances in molecular biology have led to new peptides and proteins being discovered on a regular basis, including the isolation of a number of neurotransmitter candidates. Rarely, however, do these immediately capture the attention of the scientific community. The isolation and characterization of the orexin/hypocretin peptides a decade ago resulted in a slew of studies that have helped clarified their diverse functions, including prominent roles in arousal and appetitive behavior. A number of recent studies have detailed the role of the orexins/hypocretins in attention and cognition and uncovered an involvement in schizophrenia and the mechanisms of action of antipsychotic drugs (APDs). This issue of Schizophrenia Bulletin presents several articles that review our current understanding and point to future directions for the study of the orexins/hypocretins in schizophrenia and APD actions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17728265      PMCID: PMC2779882          DOI: 10.1093/schbul/sbm096

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  80 in total

1.  Orexin-a activates phospholipase C- and protein kinase C-mediated Ca2+ signaling in dopamine neurons of the ventral tegmental area.

Authors:  K Uramura; H Funahashi; S Muroya; S Shioda; M Takigawa; T Yada
Journal:  Neuroreport       Date:  2001-07-03       Impact factor: 1.837

2.  Thalamic paraventricular nucleus neurons collateralize to innervate the prefrontal cortex and nucleus accumbens.

Authors:  M Bubser; A Y Deutch
Journal:  Brain Res       Date:  1998-03-23       Impact factor: 3.252

3.  Attention deficits in patients with narcolepsy.

Authors:  Martina Rieger; Geert Mayer; Siegfried Gauggel
Journal:  Sleep       Date:  2003-02-01       Impact factor: 5.849

Review 4.  Orexins in the regulation of the hypothalamic-pituitary-adrenal axis.

Authors:  Raffaella Spinazzi; Paola G Andreis; Gian Paolo Rossi; Gastone G Nussdorfer
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

5.  Modafinil binds to the dopamine uptake carrier site with low affinity.

Authors:  E Mignot; S Nishino; C Guilleminault; W C Dement
Journal:  Sleep       Date:  1994-08       Impact factor: 5.849

6.  Impact of modafinil on prefrontal executive function in schizophrenia.

Authors:  Michael D Hunter; Venkatasubramanian Ganesan; Iain D Wilkinson; Sean A Spence
Journal:  Am J Psychiatry       Date:  2006-12       Impact factor: 18.112

7.  Attentive and preattentive processing in narcolepsy as revealed by event-related potentials (ERPs).

Authors:  A Naumann; J Bierbrauer; H Przuntek; I Daum
Journal:  Neuroreport       Date:  2001-09-17       Impact factor: 1.837

8.  Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders.

Authors:  Bruce J Kinon; Christopher J Kaiser; Saeed Ahmed; Matthew D Rotelli; Sara Kollack-Walker
Journal:  J Clin Psychopharmacol       Date:  2005-06       Impact factor: 3.153

9.  Cognitive dysfunction in sleep disorders.

Authors:  S Fulda; H Schulz
Journal:  Sleep Med Rev       Date:  2001-12       Impact factor: 11.609

Review 10.  Narcolepsy and the hypocretin system--where motion meets emotion.

Authors:  Jerome M Siegel; Lisa N Boehmer
Journal:  Nat Clin Pract Neurol       Date:  2006-10
View more
  12 in total

1.  Cognitive activation by central thalamic stimulation: the yerkes-dodson law revisited.

Authors:  Robert G Mair; Kristen D Onos; Jacqueline R Hembrook
Journal:  Dose Response       Date:  2010-08-20       Impact factor: 2.658

Review 2.  The brain hypocretins and their receptors: mediators of allostatic arousal.

Authors:  Matthew E Carter; Jana Schaich Borg; Luis de Lecea
Journal:  Curr Opin Pharmacol       Date:  2009-02       Impact factor: 5.547

Review 3.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

4.  Orexin/hypocretin in psychiatric disorders: present state of knowledge and future potential.

Authors:  Stephanie L Borgland; Gwenaël Labouèbe
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 5.  Motivational activation: a unifying hypothesis of orexin/hypocretin function.

Authors:  Stephen V Mahler; David E Moorman; Rachel J Smith; Morgan H James; Gary Aston-Jones
Journal:  Nat Neurosci       Date:  2014-09-25       Impact factor: 24.884

6.  Role of lateral hypothalamus in two aspects of attention in associative learning.

Authors:  Daniel S Wheeler; Sandy Wan; Alexandra Miller; Nicole Angeli; Bayan Adileh; Weidong Hu; Peter C Holland
Journal:  Eur J Neurosci       Date:  2014-04-21       Impact factor: 3.386

Review 7.  The hypocretin system and psychiatric disorders.

Authors:  Fabio Pizza; Michele Magnani; Camilla Indrio; Giuseppe Plazzi
Journal:  Curr Psychiatry Rep       Date:  2014-02       Impact factor: 5.285

8.  Systemic and intrabasalis administration of the orexin-1 receptor antagonist, SB-334867, disrupts attentional performance in rats.

Authors:  Karen E Boschen; Jim R Fadel; Joshua A Burk
Journal:  Psychopharmacology (Berl)       Date:  2009-07-03       Impact factor: 4.530

9.  Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem.

Authors:  Dwight Dickinson; Philip D Harvey
Journal:  Schizophr Bull       Date:  2008-08-09       Impact factor: 9.306

10.  Genetic origin of the relationship between parental negativity and behavior problems from early childhood to adolescence: a longitudinal genetically sensitive study.

Authors:  Silvia Alemany; Frühling V Rijsdijk; Claire Margaret Alison Haworth; Lourdes Fañanás; Robert Plomin
Journal:  Dev Psychopathol       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.